Pirtobrutinib is a pharmaceutical raw material and Bruton's tyrosine kinase (BTK) inhibitor used in the manufacturing of anti-cancer medications. It is an orally bioavailable compound that binds to and inhibits BTK, thereby suppressing B cell lymphocyte proliferation and survival.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 2101700-15-4
Acalabrutinib maleate
pharmaceutical raw material
Acalabrutinib
pharmaceutical raw material
7-((4E)-3-(Aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid
pharmaceutical raw material
Anhydro simvastatin
pharmaceutical raw material
Sabarubicin
pharmaceutical raw material
Diquafosol tetrasodium
pharmaceutical raw material
5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide
FWZAWAUZXYCBKZ-NSHDSACASA-N
C[C@@H](C(F)(F)F)N1C(=C(C(=N1)C2=CC=C(C=C2)CNC(=O)C3=C(C=CC(=C3)F)OC)C(=O)N)N